Gain Therapeutics to Present Parkinson's Data
Gain Therapeutics will share early GBA1-linked Parkinson's data at scientific meetings in Milan and Washington this November.
Updated on Nov. 5, 2026 in Alzheimer’s
Gain Therapeutics, a clinical-stage biotechnology company listed on Nasdaq as GANX, will present two late-breaking posters at the 31st IAPRD World Congress on Parkinson's Disease in Milan, Italy, November 11-14, 2026. The posters cover its lead candidate rexaceract and a preclinical GCase modulator, GT-04686, for GBA1-associated Parkinson's disease.
Why it matters
Parkinson's disease, including forms linked to GBA1 gene mutations, currently has limited disease-modifying options, so early clinical and preclinical data are closely watched by patients and clinicians. These presentations signal ongoing development of candidate therapies, though the data are early-stage and not yet proof of benefit.
The presentations include an open-label extension of a Phase 1b clinical study of rexaceract in Parkinson's disease and a preclinical study of the GCase modulator GT-04686 in a GBA1 Parkinson's disease model. The extraction does not report sample sizes or measured outcomes, so the results should be considered preliminary.
The players
Gain Therapeutics
A clinical-stage biotechnology company developing treatments for neurodegenerative conditions, including Parkinson's disease, with its lead candidate rexaceract.
The details
Rexaceract (GT-02287) is being evaluated in a Phase 1b trial for Parkinson's disease with or without a GBA1 mutation. GT-04686 is described as a novel allosteric GCase modulator, a type of compound designed to act on the GCase enzyme that GBA1 mutations affect. The Neuroscience 2026 poster reports that GT-04686 reduced neuropathology and improved motor and non-motor function in a preclinical model, though these are animal-model findings.
Timeline
November 11-14, 2026: 31st IAPRD World Congress on Parkinson's Disease in Milan, Italy
November 13, 2026, 3:30-4:30 p.m. CET: Guided poster tour of the P9.8 late-breaker
November 14-18, 2026: Neuroscience 2026 annual meeting in Washington, D.C.
November 17, 2026, 8:00-9:00 a.m. EST: Presentation of poster PSTR222.06 at Neuroscience 2026
Health Landscape
GBA1 mutations are among the most common known genetic risk factors for Parkinson's disease, and therapies aimed at the GCase enzyme pathway are an active area of research. The posters add early-stage data to a pipeline that has not yet produced an approved GBA1-targeted treatment.
If you or a family member has Parkinson's disease, these posters are early signals of research direction rather than available treatments. Anyone with a known GBA1 mutation may find it worth asking a neurologist whether clinical trials targeting this pathway are an appropriate option to explore.
The takeaway
Early-stage data on GBA1-targeted Parkinson's therapies are being shared in November 2026, but they remain preliminary. Readers interested in clinical trial participation should discuss eligibility and options with their neurologist.
What happens next
Gain Therapeutics will present the GT-04686 poster at Neuroscience 2026 in Washington, D.C., on November 17, 2026, and the IAPRD poster tour takes place November 13, 2026, in Milan.
Further reading
For broader context on neurodegenerative research, explore our Alzheimer’s coverage.
Source note: This article includes information reported by The Manila times.
